Alvotech

Closed (deSPAC)

Biopharmaceutical company developing biosimilar medicines

What it is: A private company in biopharmaceutical company developing biosimilar medicines preparing to list via a SPAC merger. Full profile in progress.
What it’s doing now: Merging with Oaktree Acquisition Corp. II (OACB) — closed (despac), announced May 10, 2022.
What you should know: Data is still being assembled for this company — what is shown below is everything we have verified so far.

Profile in progress — we only publish what we can verify in filings, and for this company that work isn’t finished. Identity and deal facts above are current; business detail, financials and peers will appear as the filings are parsed.

The deal it’s entering

Alvotech is merging with Oaktree Acquisition Corp. II (OACB) currently marked Closed (deSPAC).

Headline equity value	—
Post-close ticker	ALVO

How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is Alvotech going public?

Alvotech has an approved merger with the SPAC Oaktree Acquisition Corp. II (OACB), announced May 10, 2022. The combined company expects to trade as ALVO. Deal status: Closed (deSPAC).

Does Alvotech have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.